Insight Molecular Diagnostics Inc. (IMDX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Insight Molecular Diagnostics Inc. (IMDX) Healthcare & Pipeline Overview

Insight Molecular Diagnostics Inc. (IMDX) is a biotechnology company specializing in molecular diagnostics for cancer detection. Their portfolio includes DetermaRx, a test for early-stage lung adenocarcinoma, and DetermaIO, a gene expression assay, positioning them in the competitive landscape of personalized cancer treatment solutions.

What Is the Investment Thesis for IMDX?

Insight Molecular Diagnostics Inc. (IMDX) presents a focused investment opportunity within the molecular diagnostics sector. The company's DetermaRx and DetermaIO products address critical needs in lung cancer diagnosis and treatment prediction. A key value driver is the potential for increased adoption of these tests by oncologists, leading to revenue growth. The collaboration with Life Technologies provides a catalyst for expanding market reach and enhancing assay performance. However, the company's negative profit margin of -1238.5% and relatively low gross margin of 4.7% pose significant risks. Successful commercialization and cost management are crucial for achieving profitability. The company's beta of 1.53 indicates higher volatility compared to the market, requiring careful consideration of risk tolerance.

Based on FMP financials and quantitative analysis

IMDX Key Highlights

Market capitalization of $129M reflects the company's current valuation in the biotechnology sector.

• Negative profit margin of -1238.5% indicates significant challenges in achieving profitability.
• Gross margin of 4.7% highlights the need for improved cost management and pricing strategies.
• Beta of 1.53 suggests higher volatility compared to the overall market.
• Focus on molecular diagnostics for cancer detection positions the company in a high-growth area of healthcare.

Who Are IMDX's Competitors?

IMDX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are IMDX's Key Strengths?

Proprietary DetermaRx and DetermaIO diagnostic tests.

• Expertise in molecular diagnostics and biomarker discovery.
• Collaboration with Life Technologies Corporation.
• Focus on personalized cancer treatment.

What Are IMDX's Weaknesses?

Negative profit margin and low gross margin.

• Limited market share compared to larger competitors.
• Reliance on a small number of diagnostic tests.
• High beta indicating higher volatility.

What Could Drive IMDX Stock Higher?

IMDX catalyst: Publication of clinical trial data demonstrating the efficacy of DetermaRx in predicting response to adjuvant therapy.

• Expansion of the commercial sales force to increase market penetration.
• Development of new diagnostic tests for other cancer types.

What Are the Key Risks for IMDX?

Financial-distress signal — its Altman Z-Score of -23.28 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 7 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Failure to achieve regulatory approvals for new diagnostic tests.
• Competition from larger companies with greater resources.
• Reimbursement challenges from healthcare payers.
• Dependence on key personnel and strategic partnerships.

What Are the Growth Opportunities for IMDX?

• Expansion of DetermaIO into new immuno-oncology applications: The market for immune checkpoint inhibitors is growing rapidly, creating a significant opportunity for DetermaIO to predict patient response and guide treatment decisions. The global immuno-oncology market is projected to reach $75 billion by 2028. Expanding the clinical utility of DetermaIO through additional validation studies and regulatory approvals could drive substantial revenue growth for Insight Molecular Diagnostics over the next 3-5 years.
• Increased adoption of DetermaRx in early-stage lung cancer diagnosis: Early detection and accurate staging of lung cancer are critical for improving patient outcomes. DetermaRx offers a valuable tool for identifying high-risk patients who may benefit from adjuvant therapy. Collaborating with leading oncology centers and participating in clinical trials can increase awareness and adoption of DetermaRx among oncologists. This growth opportunity has a potential timeline of 2-4 years.
• Strategic partnerships with pharmaceutical companies for companion diagnostics: Pharmaceutical companies are increasingly seeking companion diagnostics to identify patients who are most likely to respond to their targeted therapies. Insight Molecular Diagnostics can leverage its expertise in assay development and biomarker discovery to partner with pharmaceutical companies in developing and commercializing companion diagnostics. These partnerships can provide significant revenue streams and enhance the company's market position over the next 3-5 years.
• Geographic expansion into international markets: The demand for molecular diagnostics is growing globally, particularly in emerging markets with increasing cancer incidence. Insight Molecular Diagnostics can expand its market reach by establishing distribution partnerships and seeking regulatory approvals in key international markets such as Europe and Asia. This expansion strategy can contribute to long-term revenue growth and diversification over the next 5-7 years.
• Development of new diagnostic tests for other cancer types: Insight Molecular Diagnostics can leverage its technology platform and expertise to develop new diagnostic tests for other cancer types with unmet clinical needs. This diversification strategy can reduce the company's reliance on lung cancer diagnostics and create new growth opportunities. The timeline for developing and commercializing new diagnostic tests is typically 3-5 years.

What Threats Does IMDX Face?

• Competition from established players in the molecular diagnostics market.
• Regulatory hurdles and reimbursement challenges.
• Technological advancements that could render existing tests obsolete.
• Economic downturn that could reduce healthcare spending.

What Are IMDX's Competitive Advantages?

• Proprietary technology platform for developing and commercializing molecular diagnostic tests.
• Established relationships with leading oncology centers and pharmaceutical companies.
• Intellectual property protection for key diagnostic assays.
• Expertise in biomarker discovery and assay development.

What Does IMDX Do?

Insight Molecular Diagnostics Inc., formerly known as OncoCyte Corporation, was founded in 2009 and is based in Nashville, Tennessee. The company is dedicated to researching, developing, and commercializing proprietary laboratory-developed tests for cancer detection. Their flagship product, DetermaRx, is a molecular test designed for early-stage adenocarcinoma of the lung, providing clinicians with valuable information for treatment decisions. Another key offering is DetermaIO, a proprietary gene expression assay used in immuno-oncology to predict response to immune checkpoint inhibitors. In addition to their core product line, Insight Molecular Diagnostics provides biomarker discovery testing, assay design and development, and clinical trial support services. These services cater to pharmaceutical companies seeking to develop and validate novel cancer therapies. The company has a collaboration agreement with Life Technologies Corporation to develop and commercialize Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. This partnership enhances the accessibility and utility of their diagnostic tools. Insight Molecular Diagnostics aims to improve patient outcomes by providing innovative diagnostic solutions that enable personalized cancer treatment strategies.

What Products and Services Does IMDX Offer?

• Research and develop molecular diagnostic tests for cancer detection.
• Commercialize proprietary laboratory-developed tests for use in clinical practice.
• Offer DetermaRx, a molecular test for early-stage adenocarcinoma of the lung.
• Provide DetermaIO, a gene expression assay for predicting response to immune checkpoint inhibitors.
• Offer biomarker discovery testing and assay design and development services.
• Support clinical trials with biomarker testing services.

How Does IMDX Make Money?

• Generate revenue through the sale of diagnostic tests to hospitals, oncology centers, and reference laboratories.
• Provide biomarker discovery and assay development services to pharmaceutical companies.
• Collaborate with Life Technologies Corporation to commercialize diagnostic assays.
• Pursue strategic partnerships to expand market reach and product offerings.

What Industry Does IMDX Operate In?

Insight Molecular Diagnostics Inc. operates in the rapidly evolving molecular diagnostics market, driven by advancements in genomics and personalized medicine. The industry is characterized by intense competition among established players and emerging companies. Key trends include the development of non-invasive liquid biopsy tests, the integration of artificial intelligence for data analysis, and the increasing demand for companion diagnostics to guide targeted therapies. Insight Molecular Diagnostics competes with companies offering similar cancer detection and monitoring solutions. The company's success depends on its ability to differentiate its products, secure regulatory approvals, and establish strong relationships with oncologists and pharmaceutical partners.

Who Are IMDX's Key Customers?

• Hospitals and oncology centers that use diagnostic tests to guide treatment decisions.
• Reference laboratories that perform diagnostic testing on patient samples.
• Pharmaceutical companies that require biomarker discovery and assay development services.
• Patients who benefit from personalized cancer treatment strategies.

Company Profile

Insight Molecular Diagnostics Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Nashville, US. The company is led by CEO Joshua Riggs. IMDX has traded publicly since 2015.

Insight Molecular Diagnostics Inc. Financial Trajectory

Insight Molecular Diagnostics Inc. (IMDX) reported $239K in revenue for Q2 FY2026, reflecting 646.9% growth compared to the prior quarter. The company recorded a net loss of $11.3M, with diluted EPS of $-0.31. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, IMDX averaged $-0.38 in diluted EPS.

How Insight Molecular Diagnostics Inc. Is Valued

Insight Molecular Diagnostics Inc. carries a market capitalization of $129M, placing it in the micro-cap category. Analyst price targets span from $8.00 to $12.00, with a consensus of $9.75. At the current price of $3.98, that implies approximately 145% upside potential. Relative to its peer group, IMDX's quantitative score of 17/100 is below the peer average of 73/100.

Return on equity for Insight Molecular Diagnostics Inc. stands at 271.8%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -23.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.00 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -33.5%, the inverse of the P/E and a quick read on earnings relative to price.

Insight Molecular Diagnostics Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -23.28 places it in the distress zone, a signal of elevated financial risk.

Insight Molecular Diagnostics Inc. has missed Wall Street's EPS estimate in 7 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 97.2% below estimates on average.

Over the past six months, Insight Molecular Diagnostics Inc. insiders filed 27 SEC Form 4 transactions — 9 sales and 18 purchases. On net that is roughly 786K shares acquired (about $2.4M) — insiders putting money in tends to read as conviction.

IMDX Financials

IMDX Latest News

IMDX Analyst Consensus

IMDX MoonshotScore

IMDX Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources